Header
For Healthcare Professionals

India: Why Glyxambi®?

why Glyxambi Banner image

POWERFUL EFFICACY with MULTIPLE BENEFITS

3 efficacy benefits

Powerful & early
Powerful & early glycemic control11
Reduction in body weight

Reduction in body weight & Insulin resistance6
Improves ß-cell
Improves ß-cell functioning12

2 robust safety outcomes

CV & Renal safety2,3
CV & Renal safety2,3
Potential lower
Potential lower risk of GTI9

1The convenience of once-daily pill

8mm small pill10

8 mm small pill10

RETHINK THE MATH to manage T2DM

T2DM patients banner(why glyxambi)

For T2DM patients uncontrolled on Metformin with HbA1c >8%1

  • *
    IQVIA MAT May 2024. Patient numbers calculated considering average adherence to therapy as 3 months, ^eGFR cutoff lowered to 30 ml/min/1.73 m2, †https://www.accessdata.fda.gov/ drugsatfda_docs/nda/2015/2060730rig1s000Approv.pdf Accessed on: 27/04/2018, ‡http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004057/human_ med_002000.jsp&mid=WCOb01ac058001d124.pdf Accessed on: 27/04/2018.
References

  1. GLYXAMBI® India pack insert version. 15 May 2024.

  2. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128.

  3. Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69-79.

  4. Rosenstock J, Kahn SE, Johansen OE, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019;322(12):1155-1166.

  5. Wanner Ch, Inzucchi SE, Zinman B. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375(18):1801-1802.

  6. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38(3):384-393. 

  7. Hattori S. Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance. Diabetol Metab Syndr. 2018;10:93. 

  8. Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38(3):394-402. 

  9. Fadini GP, Bonora BM, Mayur S, et al. Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2018;20(3):740-744. 

  10. Data on file, Boehringer Ingelheim Pvt. Ltd. 

  11. DeFronzo RA, Lee C, Kohler S. Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials. Adv Ther. 2018;35(7):1009-1022. 

  12. Del Prato, et al. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011;13(3):258-267